1. 2006 A phase III multicenter trial comparing two different sequences of second/third line therapy (cetuximab/irinotecan followed by FOLFOX versus FOLFOX followed by cetuximab/irinotecan) in metastatic K-RAS wt colorectal cancer (mCC) patients, refractory to FOLFIRI/Bevacizumab). Issue 3 (September 2015) Authors: Cascinu, S.; Lonardi, S.; Rosati, G.; Nasti, G.; Zaniboni, A.; Romiti, A.; Aglietta, M.; Bilancia, D.; Iaffaioli, V.; Zagonel, V.; Giordano, M.; Corsi, D.; Ferraù, F.; Labianca, R.; Berardi, R.; Rulli, E.; Floriani, I. Journal: European journal of cancer Issue: Volume 51:Issue 3(2015:Feb.) Page Start: S329 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Acromegaly, genetic variants of the aryl hydrocarbon receptor pathway and environmental burden. (5th December 2017) Authors: Cannavo, S.; Trimarchi, F.; Ferraù, F. Journal: Molecular and cellular endocrinology Issue: Volume 457(2017) Page Start: 81 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Metronomic chemotherapy for advanced breast cancer patients in the real world practice: Final results of the VICTOR-6 study. (December 2019) Authors: Cazzaniga, M.E.; Pinotti, G.; Montagna, E.; Amoroso, D.; Berardi, R.; Butera, A.; Cagossi, K.; Cavanna, L.; Ciccarese, M.; Cinieri, S.; Cretella, E.; De Conciliis, E.; Febbraro, A.; Ferraù, F.; Ferzi, A.; Fiorentini, G.; Fontana, A.; Gambaro, A.R.; Garrone, O.; Gebbia, V. Journal: Breast Issue: Volume 48(2019) Page Start: 7 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗